Tandem mass spectrometry newborn screening for inborn errors of intermediary metabolism: Abnormal profile interpretation

Current Medicinal Chemistry

Volumn 19, Issue 26, 2012, Pages 4511-4522

  Fernandez Lainez C ^a   Aguilar Lemus, J J ^b   Vela Amieva, M ^a   Ibarra Gonzalez I ^c  

^a SECRETARÍA DE SALUD   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Acylcarnitines; Amino acids; Expanded newborn screening; False negative results; False positive results; Inherited metabolic disorders; Interpretation of expanded newborn screening; Maternal inherited metabolic disorders

Indexed keywords

ACETYLCARNITINE; ALANINE; ARGININE; ARGININOSUCCINIC ACID; CARNITINE; CITRULLINE; GLYCINE; HOMOCYSTEINE; METHIONINE; ORNITHINE; PHENYLALANINE; PROPIONYLCARNITINE; SUCCINYLACETONE; TYROSINE; VALINE;

AMINO ACID BLOOD LEVEL; ANALYTIC METHOD; DIET RESTRICTION; ENZYMATIC ASSAY; HUMAN; INBORN ERROR OF METABOLISM; MALNUTRITION; NEWBORN SCREENING; PROCESS DESIGN; QUALITY CONTROL; REFERENCE VALUE; REVIEW; STARVATION; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

AMINO ACID METABOLISM, INBORN ERRORS; AMINO ACIDS; BIOLOGICAL MARKERS; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; TANDEM MASS SPECTROMETRY;

EID: 84868031084     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803251539     Document Type: Review

References (134)

1. Watson, M.S.; Mann, M.Y.; Lloyd-Puryear, M.A.; Rinaldo, P.; Howell, R. Newborn Screening: Toward a Uniform Screening Panel and System - Executive Summary. Pediatrics, 2006, 117(S3), S296-S307.
2. Norman, R.; Haas, M.; Chaplin, M.; Joy, P.; Wilcken, B. Economic Evaluation of Tandem Mass Spectrometry Newborn Screening in Australia. Pediatrics, 2009, 123(2), 451-457.
3. Loeber, J.G.; Burgard, P.; Cornel, M.C.; Rigter, T.; Weinreich, S.S.; Rupp, K.; Hoffmann, G.F.; Vittozzi, L. Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 1 - From blood spot to screening result. J. Inherit. Metab. Dis., 2012, 35(4), 603-11.
4. Rinaldo, P.; Lim, J.S.; Tortorelli, S.; Gavrilov, D.; Matern, D. Newborn screening of metabolic disorders: Recent progress and future developments. Nestle Nutr. Workshop Ser. Pediatr. Program, 2008, 62, 81-93.
5. Ko, D.H.; Jun, S.H.; Park, K.U.; Song, S.H.; Kim, J.Q.; Song, J. Newborn screening for galactosemia by a second-tier multiplex enzyme assay using UPLC-MS/MS in dried blood spots. J. Inherit. Metab. Dis., 2011, 34(2), 409-414.
6. Fletcher, J.; Wilcken, B. Neonatal screening for lysosomal storage disorders. Lancet. 2012, 379(9813), 294-295.
7. McHugh, D.M.; Cameron, C.A.; Abdenur, J.E.; Abdulrahman, M.; Adair, O.; Al Nuaimi, S.A.; Åhlman, H.; Allen, J.J.; Antonozzi, I.; Archer, S.; Au, S.; Auray-Blais, C.; Baker, M.; Bamforth, F.; Beckmann, K.; Pino, G.B.; Berberich, S.L.; Binard, R.; Boemer, F.; Bonham, J.; Breen, N.N.; Bryant, S.C.; Caggana, M.; Caldwell, S.G.; Camilot, M.; Campbell, C.; Carducci, C.; Bryant, S.C.; Caggana, M.; Caldwell, S.G.; Camilot, M.; Campbell, C.; Carducci, C.; Cariappa, R.; Carlisle, C.; Caruso, U.; Cassanello, M.; Castilla, A.M.; Ramos, D.E.; Chakraborty, P.; Chandrasekar, R.; Ramos, A.C.; Cheillan, D.; Chien, Y.H.; Childs, T.A.; Chrastina, P.; Sica, Y.C.; de Juan, J.A.; Colandre, M.E.; Espinoza, V.C.; Corso, G.; Currier, R.; Cyr, D.; Czuczy, N.; D'Apolito, O.; Davis, T.; de Sain-Van der Velden, M.G.; Delgado Pecellin, C.; Di Gangi, I.M.; Di Stefano, C.M.; Dotsikas, Y.; Downing, M.; Downs, S.M.; Dy, B.; Dymerski, M.; Rueda, I.; Elvers, B.; Eaton, R.; Eckerd, B.M.; El Mougy, F.; Eroh, S.; Espada, M.; Evans, C.; Fawbush, S.; Fijolek, K.F.; Fisher, L.; Franzson, L.; Frazier, D.M.; Garcia, L.R.; Bermejo, M.S.; Gavrilov, D.; Gerace, R.; Giordano, G.; Irazabal, Y.G.; Greed, L.C.; Grier, R.; Grycki, E.; Gu, X.; Gulamali-Majid, F.; Hagar, A.F.; Han, L.; Hannon, W.H.; Haslip, C.; Hassan, F.A.; He, M.; Hietala, A.; Himstedt, L.; Hoffman, G.L.; Hoffman, W.; Hoggatt, P.; Hopkins, P.V.; Hougaard, D.M.; Hughes, K.; Hunt, P.R.; Hwu, W.L.; Hynes, J.; Ibarra-González, I.; Ingham, C.A.; Ivanova, M.; Jacox, W.B.; John, C.; Johnson, J.P.; Jónsson, J.J.; Karg, E.; Kasper, D.; Klopper, B.; Katakouzinos, D.; Khneisser, I.; Knoll, D.; Kobayashi, H.; Koneski, R.; Kozich, V.; Kouapei, R.; Kohlmueller, D.; Kremensky, I.; la Marca, G.; Lavochkin, M.; Lee, S.Y.; Lehotay, D.C.; Lemes, A.; Lepage, J.; Lesko, B.; Lewis, B.; Lim, C.; Linard, S.; Lindner, M.; Lloyd-Puryear, M.A.; Lorey, F.; Loukas, Y.L.; Luedtke, J.; Maffitt, N.; Magee, J.F.; Manning, A.; Manos, S.; Marie, S.; Hadachi, S.M.; Marquardt, G.; Martin, S.J.; Matern, D.; Mayfield Gibson, S.K.; Mayne, P.; McCallister, T.D.; McCann, M.; McClure, J.; McGill, J.J.; McKeever, C.D.; McNeilly, B.; Morrissey, M.A.; Moutsatsou, P.; Mulcahy, E.A.; Nikoloudis, D.; Norgaard-Pedersen, B.; Oglesbee, D.; Oltarzewski, M.; Ombrone, D.; Ojodu, J.; Papakonstantinou, V.; Reoyo, S.P.; Park, H.D.; Pasquali, M.; Pasquini, E.; Patel, P.; Pass, K.A.; Peterson, C.; Pettersen, R.D.; Pitt, J.J.; Poh, S.; Pollak, A.; Porter, C.; Poston, P.A.; Price, R.W.; Queijo, C.; Quesada, J.; Randell, E.; Ranieri, E.; Raymond, K.; Reddic, J.E.; Reuben, A.; Ricciardi, C.; Rinaldo, P.; Rivera, J.D.; Roberts, A.; Rocha, H.; Roche, G.; Greenberg, C.R.; Mellado, J.M.; Juan-Fita, M.J.; Ruiz, C.; Ruoppolo, M.; Rutledge, S.L.; Ryu, E.; Saban, C; Sahai, I.; García-Blanco, M.I.; Santiago-Borrero, P.; Schenone, A.; Schoos, R.; Schweitzer, B.; Scott, P.; Seashore, M.R.; Seeterlin, M.A.; Sesser, D.E.; Sevier, D.W.; Shone, S.M.; Sinclair, G.; Skrinska, V.A.; Stanley, E.L.; Strovel, E.T.; Jones, A.L.; Sunny, S.; Takats, Z.; Tanyalcin, T.; Teofoli, F.; Thompson, J.R.; Tomashitis, K.; Domingos, M.T.; Torres, J.; Torres, R.; Tortorelli, S.; Turi, S.; Turner, K.; Tzanakos, N.; Valiente, A.G.; Vallance, H.; Vela-Amieva M.; Vilarinho, L.; von Döbeln, U.; Vincent, M.F.; Vorster, B.C.; Watson, M.S.; Webster, D.; Weiss, S.; Wilcken, B.; Wiley, V.; Williams, S.K.; Willis, S.A.; Woontner, M.; Wright, K.; Yahyaoui, R.; Yamaguchi, S.; Yssel, M.; Zakowicz, W.M. Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. Genet. Med., 2011, 13(3), 230-54.
8. Rinaldo, P.; Matern, D. In: Inherited Metabolic Diseases; Hoffmann, G.F., Ed.; Springer-Verlag Berlin Heidelberg: Germany, 2010; pp. 251-261.
9. Smith, E.H.; Matern, D. Acylcarnitine analysis by tandem mass spectrometry. Curr. Protoc. Hum. Genet., 2010, S64, 17810-178120.
10. Chace, D.H.; Kalas, T.A.; Naylor, E.W. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin. Chem., 2003, 49(11), 1797-1817.
11. Chace, D.H.; Kalas, T.A.; Naylor, E.W. The application of tandem mass spectrometry to neonatal screening for inherited disorders of intermediary metabolism. Annu. Rev. Genomics. Hum. Genet., 2002, 3, 17-45.
12. Chace, D.H.; Kalas, T.A. A biochemical perspective on the use of tandem mass spectrometry for newborn screening and clinical testing. Clin. Biochem., 2005, 38(4), 296-309.
13. Garg, U.; Dasouki, M. Expanded newborn screening of inherited metabolic disorders by tandem mass spectrometry: clinical and laboratory aspects. Clin. Biochem., 2006, 39(4), 315-332.
14. Lehotay, D.C.; Hall, P.; Eichhorst, J.C.; Etter, M.L.; Greenberg, C.R. LC-MS/MS progress in newborn screening. Clin. Biochem., 2011, 44(1), 21-31.
15. Carpenter, K.H.; Wiley, V. Application of tandem mass spectrometry to biochemical genetics and newborn screening. Clin. Chim. Acta., 2002, 322(1-2), 1-10.
16. Frazier, D.M.; Millington, D.S.; McCandless, S.E.; Koeberl, D.D.; Weavil, S.D.; Chaing, S.H.; Muenzer, J. The tandem mass spectrometry newborn screening experience in North Carolina: 1997-2005. J. Inherit. Metab. Dis., 2006, 29(1), 76-85.
17. Zytkovicz, T.H.; Fitzgerald, E.F.; Marsden, D.; Larson, C.A.; Shih, V.E.; Johnson, D.M.; Strauss, A.W.; Comeau, A.M.; Eaton, R.B.; Grady, G.F. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin. Chem., 2001, 47(11), 1945-1955.
18. la Marca, G.; Malvagia, S.; Casetta, B.; Pasquini, E.; Donati, M.A.; Zammarchi, E. Progress in expanded newborn screening for metabolic conditions by LC-MS/MS in Tuscany: update on methods to reduce false tests. J. Inherit. Metab. Dis., 2008, 31(Suppl 2), S395-S404.
19. Sun, W.; Wang, Y.; Yang, Y.; Wang, J.; Cao, Y.; Luo, F.; Lu, W.; Peng, Y.; Yao, H.; Qiu, P. The screening of inborn errors of metabolism in sick Chinese infants by tandem mass spectrometry and gas chromatography/mass spectrometry. Clin. Chim. Acta., 2011, 412(13-14), 1270-1274.
20. Lashley, F.R. Newborn screening: New opportunities and new challenges. Newborn Infant. Nurs. Rev., 2002, 2(4), 228-242.
21. la Marca, G.; Rizzo, C. Analysis of organic acids and acylglycines for the diagnosis of related inborn errors of metabolism by GC- and HPLC-MS. Methods Mol. Biol., 2011, 708, 73-98.
22. Fingerhut, R.; Simon, E.; Maier, E.M.; Hennermann, J.B.; Wendel, U. Maple syrup urine disease: newborn screening fails to discriminate between classic and variant forms. Clin. Chem., 2008, 54(10), 1739-1741.
23. Bodner-Leidecker, A.; Wendel, U.; Saudubray, J.M.; Schadewaldt, P. Branched-chain L-amino acid metabolism in classical maple syrup urine disease after orthotopic liver transplantation. J. Inherit. Metab. Dis., 2000, 23(8), 805-818.
24. Jeong, J.S.; Sim, H.J.; Lee, Y.M.; Yoon, H.R.; Kwon, H.J.; Hong, S.P. Chromatographic diagnosis of maple syrup urine disease by measuring the Lalloisoleucine/L-phenylalanine ratio in dried blood spots. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2011, 879(22), 2171-2174.
25. Erez, A.; Nagamani, S.C.; Lee, B. Argininosuccinate lyase deficiencyargininosuccinic aciduria and beyond. Am. J. Med. Genet. C. Semin. Med. Genet., 2011, 157(1), 45-53.
26. Saheki, T.; Kobayashi, K.; Iijima, M.; Nishi, I.; Yasuda, T.; Yamaguchi, N.; Gao, H.Z.; Jalil, M.A.; Begum, L.; Li, M.X. Pathogenesis and pathophysiology of citrin (a mitochondrial aspartate glutamate carrier) deficiency. Metab. Brain Dis., 2002, 17(4), 335-346.
27. Mudd, S.H. Hypermethioninemias of genetic and non-genetic origin: A review. Am. J. Med. Genet. C. Semin. Med. Genet., 2011, 157(1), 3-32.
28. Ruetschi, U.; Cerone, R.; Perez-Cerda, C.; Schiaffino, M.C.; Standing, S.; Ugarte, M.; Holme, E. Mutations in the 4-hydroxyphenylpyruvate dioxygenase gene (HPD) in patients with tyrosinemia type III. Hum. Genet., 2000, 106(6), 654-662.
29. Ellaway, C.J.; Holme, E.; Standing, S.; Preece, M.A.; Green, A.; Ploechl, E.; Ugarte, M.; Trefz, F.K.; Leonard, J.V. Outcome of tyrosinaemia type III. J. Inherit. Metab. Dis., 2001, 24(8), 824-832.
30. Crombez, E.A.; Cederbaum, S.D. Hyperargininemia due to liver arginase deficiency. Mol. Genet. Metab., 2005, 84(3), 243-251.
31. Longo, N. Disorders of biopterin metabolism. J. Inherit. Metab. Dis., 2008, 32(3), 333-342.
32. Ibarra-Gonzalez, I.; Fernandez-Lainez, C.; Vela-Amieva, M. Clinical and biochemical characteristics of patients with urea cycle disorders in a developing country. Clin. Biochem., 2010, 43(4-5), 461-466.
33. Brusilow, W. S. In: The metabolic and molecular bases of inherited disease; Scriver, C.R.; Beaudet, A.L.; Valle, D., Eds.; McGraw Hill Inc: USA, 2001; pp 1909-1963.
34. Kurokawa, K.; Yorifuji, T.; Kawai, M.; Momoi, T.; Nagasaka, H.; Takayanagi, M.; Kobayashi, K.; Yoshino, M.; Kosho, T.; Adachi, M.; Otsuka, H.; Yamamoto, S.; Murata, T.; Suenaga, A.; Ishii, T.; Terada, K.; Shimura, N.; Kiwaki, K.; Shintaku, H.; Yamakawa, M.; Nakabayashi, H.; Wakutani, Y.; Nakahata, T. Molecular and clinical analyses of Japanese patients with carbamoylphosphate synthetase 1 (CPS1) deficiency. J. Hum. Genet., 2007, 52(4), 349-354.
35. Hamosh, A. In: The metabolic and molecular bases of inherited disease; Scriver, C.R.; Beaudet, A.L.; Valle, D., Eds.; McGraw Hill Inc: USA, 2001; pp 2064-2078.
36. Camacho, J.A.; Mardach, R.; Rioseco-Camacho, N.; Ruiz-Pesini, E.; Derbeneva, O.; Andrade, D.; Zaldivar, F.; Qu, Y.; Cederbaum, S.D. Clinical and functional characterization of a human ORNT1 mutation (T32R) in the hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome. Pediatr. Res., 2006, 60(4), 423-429.
37. Kobayashi, H.; Hasegawa, Y.; Endo, M.; Purevsuren, J.; Yamaguchi, S. ESIMS/MS study of acylcarnitine profiles in urine from patients with organic acidemias and fatty acid oxidation disorders. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2007, 855(1), 80-87.
38. Ogier de Baulny, H.; Saudubray, J.M. Branched-chain organic acidurias. Semin. Neonatol., 2002, 7(1), 65-74.
39. Van Hove, J.L.; Josefsberg, S.; Freehauf, C.; Thomas, J.A.; Thuy le, P.; Barshop, B.A.; Woontner, M.; Mock, D.M.; Chiang, P.W.; Spector, E.; Meneses-Morales, I.; Cervantes-Roldan, R.; Leon-Del-Rio, A. Management of a patient with holocarboxylase synthetase deficiency. Mol. Genet. Metab., 2008, 95(4), 201-205.
40. Yokoi, K.; Ito, T.; Maeda, Y.; Nakajima, Y.; Kurono, Y.; Sugiyama, N.; Togari, H. A case of holocarboxylase synthetase deficiency with insufficient response to prenatal biotin therapy. Brain Dev., 2009, 31, (10), 775-778.
41. Sass, J.O.; Forstner, R.; Sperl, W. 2-Methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency: impaired catabolism of isoleucine presenting as neurodegenerative disease. Brain Dev., 2004, 2(1), 12-14.
42. Koeberl, D.D.; Young, S.P.; Gregersen, N.S.; Vockley, J.; Smith, W.E.; Benjamin, D.K., Jr.; An, Y.; Weavil, S.D.; Chaing, S.H.; Bali, D.; McDonald, M.T.; Kishnani, P.S.; Chen, Y.T.; Millington, D.S. Rare disorders of metabolism with elevated butyryl- and isobutyryl-carnitine detected by tandem mass spectrometry newborn screening. Pediatr. Res., 2003, 54(2), 219-223.
43. Oglesbee, D.; He, M.; Majumder, N.; Vockley, J.; Ahmad, A.; Angle, B.; Burton, B.; Charrow, J.; Ensenauer, R.; Ficicioglu, C.H.; Keppen, L.D.; Marsden, D.; Tortorelli, S.; Hahn, S.H.; Matern, D. Development of a newborn screening follow-up algorithm for the diagnosis of isobutyryl-CoA dehydrogenase deficiency. Genet. Med., 2007, 9(2), 108-116.
44. Pedersen, C.B.; Bischoff, C.; Christensen, E.; Simonsen, H.; Lund, A.M.; Young, S.P.; Koeberl, D.D.; Millington, D.S.; Roe, C.R.; Roe, D.S.; Wanders, R.J.; Ruiter, J.P.; Keppen, L.D.; Stein, Q.; Knudsen, I.; Gregersen, N.; Andresen, B.S. Variations in IBD (ACAD8) in children with elevated C4-carnitine detected by tandem mass spectrometry newborn screening. Pediatr. Res., 2006, 60(3), 315-320.
45. Heberle, L.C.; Al Tawari, A.A.; Ramadan, D.G.; Ibrahim, J.K. Ethylmalonic encephalopathy-report of two cases. Brain Dev., 2006, 28(5), 329-331.
46. Di Rocco, M.; Caruso, U.; Briem, E.; Rossi, A.; Allegri, A.E.; Buzzi, D.; Tiranti, V. A case of ethylmalonic encephalopathy with atypical clinical and biochemical presentation. Mol. Genet. Metab., 2006, 89(4), 395-397.
47. Nowaczyk, M.J.; Lehotay, D.C.; Platt, B.A.; Fisher, L.; Tan, R.; Phillips, H.; Clarke, J.T. Ethylmalonic and methylsuccinic aciduria in ethylmalonic encephalopathy arise from abnormal isoleucine metabolism. Metabolism, 1998, 47(7), 836-839.
48. Lindner, M.; Ho, S.; Fang-Hoffmann, J.; Hoffmann, G.F.; Kolker, S. Neonatal screening for glutaric aciduria type I: strategies to proceed. J. Inherit. Metab. Dis., 2006, 29(2-3), 378-382.
49. Hedlund, G.L.; Longo, N.; Pasquali, M. Glutaric acidemia type 1. Am. J. Med. Genet. C. Semin. Med. Genet., 2006, 142C(2), 86-94.
50. Hsieh, C.T.; Hwu, W.L.; Huang, Y.T.; Huang, A.C.; Wang, S.F.; Hu, M.H.; Chien, Y.H. Early detection of glutaric aciduria type I by newborn screening in Taiwan. J. Formos. Med. Assoc., 2008, 107(2), 139-144.
51. Al-Dirbashi, O.Y.; Fisher, L.; McRoberts, C.; Siriwardena, K.; Geraghty, M.; Chakraborty, P. Identification of a neonate with hepatorenal tyrosinemia by combined routine newborn screening for succinylacetone, acylcarnitines and amino acids. Clin. Biochem., 2010, 43, 691-693.
52. Strauss, K.A.; Puffenberger, E.G.; Robinson, D.L.; Morton, D.H. Type I glutaric aciduria, part 1: natural history of 77 patients. Am. J. Med. Genet. C. Semin. Med. Genet., 2003, 121C(1), 38-52.
53. Kolker, S.; Garbade, S.F.; Greenberg, C.R.; Leonard, J.V.; Saudubray, J.M.; Ribes, A.; Kalkanoglu, H.S.; Lund, A.M.; Merinero, B.; Wajner, M.; Troncoso, M.; Williams, M.; Walter, J.H.; Campistol, J.; Marti-Herrero, M.; Caswill, M.; Burlina, A.B.; Lagler, F.; Maier, E.M.; Schwahn, B.; Tokatli, A.; Dursun, A.; Coskun, T.; Chalmers, R.A.; Koeller, D.M.; Zschocke, J.; Christensen, E.; Burgard, P.; Hoffmann, G.F. Natural history, outcome, and treatment efficacy in children and adults with glutaryl-CoA dehydrogenase deficiency. Pediatr. Res., 2006, 59(6), 840-847.
54. Vockley, J.; Ensenauer, R. Isovaleric acidemia: new aspects of genetic and phenotypic heterogeneity. Am. J. Med. Genet. C. Semin. Med. Genet., 2006, 142C(2), 95-103.
55. Loots, D.T.; Erasmus, E.; Mienie, L.J. Identification of 19 new metabolites induced by abnormal amino acid conjugation in isovaleric acidemia. Clin. Chem., 2005, 51(8), 1510-1512.
56. van Calcar, S.C.; Gleason, L.A.; Lindh, H.; Hoffman, G.; Rhead, W.; Vockley, G.; Wolff, J.A.; Durkin, M.S. 2-methylbutyryl-CoA dehydrogenase deficiency in Hmong infants identified by expanded newborn screen. W.M.J., 2007, 106(1), 12-15.
57. Korman, S.H.; Andresen, B.S.; Zeharia, A.; Gutman, A.; Boneh, A.; Pitt, J.J. 2-ethylhydracrylic aciduria in short/branched-chain acyl-CoA dehydrogenase deficiency: application to diagnosis and implications for the Rpathway of isoleucine oxidation. Clin. Chem., 2005, 51(3), 610-617.
58. Korman, S.H. Inborn errors of isoleucine degradation: a review. Mol. Genet. Metab., 2006, 89(4), 289-299.
59. Andresen, B.S.; Christensen, E.; Corydon, T.J.; Bross, P.; Pilgaard, B.; Wanders, R.J.; Ruiter, J.P.; Simonsen, H.; Winter, V.; Knudsen, I.; Schroeder, L.D.; Gregersen, N.; Skovby, F. Isolated 2-methylbutyrylglycinuria caused by short/branched-chain acyl-CoA dehydrogenase deficiency: identification of a new enzyme defect, resolution of its molecular basis, and evidence for distinct acyl-CoA dehydrogenases in isoleucine and valine metabolism. Am. J. Hum. Genet., 2000, 67(5), 1095-1103.
60. Catanzano, F.; Ombrone, D.; Di Stefano, C.; Rossi, A.; Nosari, N.; Scolamiero, E.; Tandurella, I.; Frisso, G.; Parenti, G.; Ruoppolo, M.; Andria, G.; Salvatore, F. The first case of mitochondrial acetoacetyl-CoA thiolase deficiency identified by expanded newborn metabolic screening in Italy: the importance of an integrated diagnostic approach. J. Inherit. Metab. Dis., 2010, DOI: 10.1007/s10545-009-9028-3: Available from: URL'.http://www.springerlink. com/content/qxv8612p7005q128/.
61. Sewell, A.C.; Herwig, J.; Wiegratz, I.; Lehnert, W.; Niederhoff, H.; Song, X.Q.; Kondo, N.; Fukao, T. Mitochondrial acetoacetyl-CoA thiolase (betaketothiolase) deficiency and pregnancy. J. Inherit. Metab. Dis., 1998, 21(4), 441-442.
62. Cazorla, M.R.; Verdu, A.; Perez-Cerda, C.; Ribes, A. Neuroimage findings in 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency. Pediatr. Neurol., 2007, 36(4), 264-267.
63. Zschocke, J.; Ruiter, J.P.; Brand, J.; Lindner, M.; Hoffmann, G.F.; Wanders, R.J.; Mayatepek, E. Progressive infantile neurodegeneration caused by 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency: a novel inborn error of branched-chain fatty acid and isoleucine metabolism. Pediatr. Res., 2000, 48(6), 852-855.
64. Reimão, S.; Morgado, C.; Almeida, I.T.; Silva, M.; Real, H.C.; Campos, J. 3-Hydroxy-3-methylglutaryl-coenzyme A lyase deficiency: Initial presentation in a young adult. J. Inherit. Metab. Dis., 2009, DOI: 10.1007/s10545-009-1048-5: Available from: URL'. http://www.springerlink.com/ content/c778439v144l1w33/.
65. Leung, A.A.; Chan, A.K.; Ezekowitz, J.A.; Leung, A.K. A Case of dilated cardiomyopathy associated with 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG CoA) lyase deficiency. Case report Med, 2009, 2009, 183125, DOI: 10.1155/2009/183125: Available from: URL'. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2773375/? tool=pubmed.
66. Vargas, C.R.; Sitta, A.; Schmitt, G.; Ferreira, G.C.; Cardoso, M.L.; Coelho, D.; Gibson, K.M.; Wajner, M. Incidence of 3-hydroxy-3-methylglutaryl- coenzyme A lyase (HL) deficiency in Brazil, South America. J. Inherit. Metab. Dis., 2007, DOI: 10.1007/s10545-007-0756-y: Available from: URL'. http://www.springerlink.com/content/e5763250245487hv/fulltext.pdf.
67. Ensenauer, R.; Muller, C.B.; Schwab, K.O.; Gibson, K.M.; Brandis, M.; Lehnert, W. 3-Methylglutaconyl-CoA hydratase deficiency: a new patient with speech retardation as the leading sign. J. Inherit. Metab. Dis., 2000, 23(4), 341-344.
68. Kumps, A.; Duez, P.; Mardens Y. Metabolic, nutritional, iatrogenic, and artifactual sources of urinary organic acids: a comprehensive table. Clin. Chem., 2002, 48(5), 708-717.
69. Sweetman, L. In: The metabolic and molecular bases of inherited disease; Scriver, C.R.; Beaudet, A.L.; Valle, D., Eds.; McGraw Hill Inc: USA, 2001; pp 2125-2193.
70. Santer, R.; Fingerhut, R.; Lassker, U.; Wightman, P.J.; Fitzpatrick, D.R.; Olgemoller, B.; Roscher, A.A. Tandem mass spectrometric determination of malonylcarnitine: diagnosis and neonatal screening of malonyl-CoA decarboxylase deficiency. Clin. Chem., 2003, 49(4), 660-662.
71. Marin-Valencia, I.; Roe, C.R.; Pascual, J.M. Pyruvate carboxylase deficiency: mechanisms, mimics and anaplerosis. Mol. Genet. Metab., 2010, 101(1), 9-17
72. Banta-Wright, S.A.; Shelton, K.C. Bennett, M.J. Disorders of Fatty Acid Oxidation in the Era of Tandem Mass Spectrometry in Newborn Screening. Newborn. Infant. Nurs. Rev., 2008, 8(1), 18-29.
73. Schimmenti, L.A.; Crombez, E.A.; Schwahn, B.C.; Heese, B.A.; Wood, T.C.; Schroer, R.J.; Bentler, K.; Cederbaum, S.; Sarafoglou, K.; McCann, M.; Rinaldo, P.; Matern, D.; di San Filippo, C.A.; Pasquali, M.; Berry, S.A.; Longo, N. Expanded newborn screening identifies maternal primary carnitine deficiency. Mol. Genet. Metab., 2007, 90(4), 441-445.
74. Kinali, M.; Olpin, S.E.; Clayton, P.T.; Daubeney, P.E.; Mercuri, E.; Manzur, A.Y.; Tein, I.; Leonard, J.; Muntoni, F. Diagnostic difficulties in a case of primary systemic carnitine deficiency with idiopathic dilated cardiomyopathy. Eur. J. Paediatr. Neurol., 2004, 8(4), 217-219.
75. Lee, N.C.; Tang, N.L.; Chien, Y.H.; Chen, C.A.; Lin, S.J.; Chiu, P.C.; Huang, A.C.; Hwu, W.L. Diagnoses of newborns and mothers with carnitine uptake defects through newborn screening. Mol. Genet. Metab., 2010, 100(1), 46-50.
76. Rose, E.C.; di San Filippo, C.A.; Ndukwe Erlingsson, U.C.; Ardon, O.; Pasquali, M.; Longo, N. Genotype-phenotype correlation in primary carnitine deficiency. Hum. Mutat., 2012, 33(1), 118-123.
77. Moczulski, D.; Majak, I.; Mamczur, D. An overview of beta-oxidation disorders. Postepy. Hig. Med. Dosw. (Online)., 2009, 63, 266-277.
78. Roe, C.R.; Millington, D.S.; Norwood, D.L.; Kodo, N.; Sprecher, H.; Mohammed, B.S.; Nada, M.; Schulz, H.; McVie, R. 2,4-Dienoyl-coenzyme A reductase deficiency: a possible new disorder of fatty acid oxidation. J. Clin. Invest., 1990, 85(5), 1703-1707.
79. Shigematsu, Y.; Hirano, S.; Hata, I.; Tanaka, Y.; Sudo, M.; Tajima, T.; Sakura, N.; Yamaguchi, S.; Takayanagi, M. Selective screening for fatty acid oxidation disorders by tandem mass spectrometry: difficulties in practical discrimination. J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci., 2003, 792(1), 63-72.
80. Wanders, R.J.; Ruiter, J.P.; L, I.J.; Waterham, H.R.; Houten, S.M. The enzymology of mitochondrial fatty acid beta-oxidation and its application to follow-up analysis of positive neonatal screening results. J. Inherit. Metab. Dis., 2010, 33(5), 479-494.
81. Tsuburaya, R.; Sakamoto, O.; Arai, N.; Kobayashi, H.; Hasegawa, Y.; Yamaguchi, S.; Shigematsu, Y.; Takayanagi, M.; Ohura, T.; Tsuchiya, S. Molecular analysis of a presymptomatic case of carnitine palmitoyl transferase I (CPT I) deficiency detected by tandem mass spectrometry newborn screening in Japan. Brain Dev., 2010, 32(5), 409-411.
82. Bonnefont, J.P.; Djouadi, F.; Prip-Buus, C.; Gobin, S.; Munnich, A.; Bastin, J. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol. Aspects. Med, 2004, 25(5-6), 495-520.
83. Rubio-Gozalbo, M.E.; Vos, P.; Forget, P.P.; Van Der Meer, S.B.; Wanders, R.J.; Waterham, H.R.; Bakker, J.A. Carnitine-acylcarnitine translocase deficiency: case report and review of the literature. Acta Paediatr., 2003, 92(4), 501-504.
84. Rubio-Gozalbo, M.E.; Bakker, J.A.; Waterham, H.R.; Wanders, R.J. Carnitine-acylcarnitine translocase deficiency, clinical, biochemical and genetic aspects. Mol. Aspects Med., 2004, 25(5-6), 521-532.
85. Rector, R.S.; Ibdah, J.A. Fatty acid oxidation disorders: maternal health and neonatal outcomes. Semin. Fetal Neonatal Med., 2010, 15(3), 122-128.
86. Region 4 Genetics Collaborative. MS/MS data project. http://www. region4genetics.org/msms-data-project/data-project-home.aspx (Accessed Nov 11, 2011).
87. Van Hove, J.L.; Kahler, S.G.; Feezor, M.D.; Ramakrishna, J.P.; Hart, P.; Treem, W.R.; Shen, J.J.; Matern, D.; Millington, D.S. Acylcarnitines in plasma and blood spots of patients with long-chain 3-hydroxyacyl-coenzyme A dehydrogenase defiency. J. Inherit. Metab. Dis., 2000, 23(6), 571-582.
88. Sykut-Cegielska, J.; Gradowska, W.; Piekutowska-Abramczuk, D.; Andresen, B.S.; Olsen, R.K.; Oltarzewski, M.; Pronicki, M.; Pajdowska, M.; Bogdanska, A.; Jablonska, E.; Radomyska, B.; Kusmierska, K.; KrajewskaWalasek, M.; Gregersen, N.; Pronicka, E. Urgent metabolic service improves survival in long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency detected by symptomatic identification and pilot newborn screening. J. Inherit. Metab. Dis., 2011, 34(1), 185-195.
89. Chapman, K.A.; Bennett, M.J.; Sondheimer, N. Increased C3-carnitine in a healthy premature infant. Clin. Chem., 2008, 54(11), 1914-1918.
90. Campbell, C.D.; Ganesh, J.; Ficicioglu, C. Two newborns with nutritional vitamin B12 deficiency: challenges in newborn screening for vitamin B12 deficiency. Haematologica., 2005, 90(12 Suppl), ECR45.
91. Marble, M.; Copeland, S.; Khanfar, N.; Rosenblatt, D.S. Neonatal vitamin B12 deficiency secondary to maternal subclinical pernicious anemia: identi- fication by expanded newborn screening. J. Pediatr., 2008, 152(5), 731-733.
92. Hinton, C.F.; Ojodu, J.A,; Fernhoff, P.M.; Rasmussen, S.A.; Scanlon, K.S.; Hannon, W.H. Maternal and neonatal vitamin B12 deficiency detected through expanded newborn screening-United States, 2003-2007. J. Pediatr., 2010, 157(1), 162-163.
93. Stratton, S.L.; Horvath, T.D.; Bogusiewicz, A.; Matthews, N.I.; Henrich, C.L.; Spencer, H.J.; Moran, J.H.; Mock, D.M. Plasma concentration of 3-hydroxyisovaleryl carnitine is an early and sensitive indicator of marginal biotin deficiency in humans. Am. J. Clin. Nutr., 2010, 92(6), 1399-1405.
94. Frazier, D.M. In: Nutrition management of patients with inherited metabolic disorders; Acosta B. P., Eds.; Jones and Bartlett Publishers: Sudbury, 2010; pp. 21-65.
95. Hsu, H.W.; Zytkovicz, T.H.; Comeau, A.M.; Strauss, A.W.; Marsden, D.; Shih, V.E.; Grady, G.F.; Eaton, R.B. Spectrum of medium-chain acyl-CoA dehydrogenase deficiency detected by newborn screening. Pediatrics., 2008, 121(5), e1108-1114.
96. Millington, D.S. In Physician's guide to the laboratory diagnosis of metabolic diseases. Blau, N.; Duran, M.; Blaskovics, E.M.; Michael-Gibson, K., Eds.; Springer: Berlin, 2003, pp. 57-76.
97. Oladipo, O.O.; Weindel, A.L.; Saunders, A.N.; Dietzen, D.J. Impact of premature birth and critical illness on neonatal range of plasma amino acid concentrations determined by LC-MS/MS. Mol. Genet. Metab., 2011, 104(4), 476-479.
98. Mudd, H.S.; Braverman, N.; Pomper, M.; Tezcan, K.; Kronick, J.; Jayakar, P.; Garganta, C.; Ampola, M.G.; Levy, H.L.; McCandless, S.E.; Wiltse, H.; Stabler, S.P.; Allen, R.H.; Wagner, C.; Borschel, M.W. Infantile hypermethioninemia and hyperhomocysteinemia due to high methionine intake: a diagnostic trap. Mol. Genet. Metab., 2003, 79(1), 6-16.
99. Chace, D.H.; De Jesús, V.R.; Lim, T.H.; Hannon, W.H.; Spitzer, A.R. Tandem mass spectrometric identification of dextrose markers in dried-blood spots from infants receiving total parenteral nutrition. Clin. Chim. Acta., 2010, 411(21-22), 1806-1816.
100. Shih, E.V. In: Physician's guide to the laboratory diagnosis of metabolic diseases. Blau, N.; Duran, M.; Blaskovics, E.M.; Michael-Gibson, K., Eds.; Springer: Berlin, 2003; pp. 11-26.
101. Duran, M. In: Laboratory guide to the methods in biochemical genetics; Blau, N.; Duran, M.; Gibson, K.M., Eds.; Springer: Berlin, 2008; pp. 53-89.
102. Dietzen, D.J.; Rinaldo, P.; Whitley, R.J.; Rhead, W.J.; Hannon, W.H.; Garg, U.C. National academy of clinical biochesmistry laboratory medicine practice guidelines: follow-up testing for metabolic disease identified by expanded newborn screening using tandem mass spectrometry; executive summary. Clin. Chem., 2009, 55(9), 1615-1626.
103. Nakajima, Y.; Ito, T.; Maeda, Y.; Ichiki, S.; Kobayashi, S.; Ando, N.; Hussein, M.H.; Kurono, Y.; Sugiyama, N.; Togari, H. Evaluation of valproate effects on acylcarnitine in epileptic children by LC-MS/MS. Brain. Dev., 2011, 33(10), 816-823.
104. Werner, T.; Treiss, I.; Kohlmueller, D.; Mehlem, P.; Teich, M.; Longin, E.; Gerstner, T.; Koenig, S.A.; Schulze, A. Effects of valproate on acylcarnitines in children with epilepsy using ESI-MS/MS. Epilepsia., 2007, 48(1), 72-76.
105. Abdenur, J.E.; Chamoles, N.A.; Guinle, A.E.; Schenone, A.B.; Fuertes, A.N. Diagnosis of isovaleric acidaemia by tandem mass spectrometry: false positive result due to pivaloylcarnitine in a newborn screening programme. J. Inherit. Metab. Dis., 1998, 21(6), 624-630.
106. Matern, D.; Tortorelli, S.; Oglesbee, D.; Gavrilov, D.; Rinaldo, P., Reduction of the false-positive rate in newborn screening by implementation of MS/MS-based second-tier tests: the Mayo Clinic experience (2004-2007). J. Inherit. Metab. Dis., 2007, 30(4), 585-592.
107. Matern, D. In: Laboratory guide to the methods in biochemical genetics; Blau, N.; Duran, M.; Gibson, K.M., Eds.; Springer: Germany, 2008; pp. 171-206.
108. Eichhorst, J.; Alcorn, J.; Lepage, J.; Etter, M.; Antonishyn, N.A.; Fitterer, B.; Birch, D.A.; Agopsowicz, K.L.; Ruthnum, L.; Greenberg, C.R.; Lehotay, D.C. Elevated neonatal 3-OH isovalerylcarnitine due to breast milk sources in maternal 3-MCC deficiency. Mol. Genet. Metab., 2010, 101(1), 84-86.
109. Arnold, G.L.; Koeberl, D.D.; Matern, D.; Barshop, B.; Braverman, N.; Burton, B.; Cederbaum, S.; Fiegenbaum, A.; Garganta, C.; Gibson, J.; Goodman, S.I.; Harding, C.; Kahler, S.; Kronn, D.; Longo, N. A Delphi-based consensus clinical practice protocol for the diagnosis and management of 3-methylcrotonyl CoA carboxylase deficiency. Mol. Genet. Metab., 2008, 93(4), 363-370.
110. Scriver, R.C. In: The metabolic and molecular bases of inherited disease; Scriver, C.R.; Beaudet, A.L.; Valle, D., Eds.; McGraw Hill Inc: New York, 2001; pp. 1667-1724.
111. Crombez, E.A., Cederbaum, S.D.; Spector, E.; Chan, E.; Salazar, D.; Neidich, J.; Goodman, S. Maternal glutaric acidemia, type I identified by newborn screening. Mol. Genet. Metab., 2008, 94(1), 132-134.
112. El-Hattab, A.W.; Li, F.Y.; Shen, J.; Powell, B.R.; Bawle, E.V.; Adams, D.J.; Wahl, E.; Kobori, J.A.; Graham, B.; Scaglia, F.; Wong, L.J. Maternal systemic primary carnitine deficiency uncovered by newborn screening: clinical, biochemical, and molecular aspects. Genet. Med., 2010, 12(1), 19-24.
113. Lewin, D.A.; Weiner, M.P. Molecular biomarkers in drug development. D.D.T., 2004, 9(22), 976-983.
114. Millington, D.S.; Stevens, R.D. In: Metabolic profiling, methods in molecular biology; Metz, T.O., Ed.; Springer Science+Business Media: New York, 2011; pp. 55-72.
115. Mitchell, G.A.; Grompe, M.; Lambert, M.; Tanguay, R.M. In: The metabolic and molecular basis of inherited metabolic disease; Scriver, C.R.; Beaudet, A.L.; Valle, D., Eds.; McGraw Hill Inc: New York, 2001; pp. 1777-1797.
116. Allard, P.; Genier, A.; Korson, M.S.; Zytkovicz, T.H. Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots. Clin. Biochem., 2004, 37(11), 1010-15.
117. Al-Dirbashi, O.Y.; Kolker, S.; Ng, D.; Fisher, L.; Rupar, T.; Lepage, N.; Rashed, M.S.; Santa, T.; Goodman, S.I.; Geraghty, M.T.; Zschocke, J.; Christensen, E.; Hoffmann, G.F.; Chakraborty, P. Diagnosis of glutaric aciduria type 1 by measuring 3-hydroxyglutaric acid in dried urine spots by liquid chromatography tandem mass spectrometry. J. Inherit. Metab. Dis., 2011, 34(1), 173-180.
118. Gurian, E.A.; Kinnamon, D.D.; Henry, J.J.; Waisbren S.E. Expanded newborn screening for biochemical disorders: the effect of a false-positive result. Pediatrics., 2006, 117(6), 1915-1921.
119. Malvagia, S.; La Marca, G.; Casetta, B.; Gasperini, S.; Pasquini, E.; Donati, M.A.; Zammarchi, E. Falsely elevated C4-carnitine as expression of glutamate formiminotransferase deficiency in tandem mass spectrometry newborn screening. J. Mass. Spec., 2006, 41(2), 263-65.
120. Rinaldo, P.; Zafari, S.; Tortorelli, S.; Matern, D. Making the case for objective performance metrics in newborn screening by tandem mass spectrometry. Ment. Retard. Dev. Disabil. Res. Rev., 2006, 12(4), 255-261.
121. De Jesús, V.R.; Mei, J.V.; Bell, C.J.; Hannon, W.H. Improving and assuring newborn screening laboratory quality worldwide: 30-year experience at the Centers for Disease Control and Prevention. Semin. Perinatol., 2010, 34(2), 125-133.
122. Howell, R.R. Quality improvement of newborn screening in real time. Genet. Med., 2011, 13(3), 205.
123. Lepage, N.; McDonald, N.; Dallaire, L.; Lambert, M. Age-specific distribution of plasma amino acid concentrations in a healthy pediatric population. Clin. Chem., 1997, 43(12), 2397-2402.
124. Cavedon, C.T.; Bourdoux, P.; Mertens, K.; Van-Thi, H.V.; Herremans, N.; de Laet, C.; Goyens, P. Age-related variations in acylcarnitine and free carnitine concentrations measured by tandem mass spectrometry. Clin. Chem., 2005, 51(4), 745-752.
125. De, T.; Kruthika-Vinod, T.P.; Nagaraja, D.; Christopher, R. Postnatal varia- tions in blood free and acylcarnitines. J. Clin. Lab. Anal., 2011, 25(2), 126-129.
126. Miller, J.; Tuerck, J.; Awad, K.; Chace, D.H.; Copeland, S.; Rasmussen, S.A.; Rien, L.; Valentine, C.J.; Webster, D.R.; Wilcken, B. Clinical and Laboratory Standards Institute (CLSI), Newborn screening for preterm, low birth weight, and sick newborns; approved guideline. CLSI document I/LA31-A. Clinical and Laboratory Standards Institute: Wayne, PA, 2009.
127. Napolitano, N.; Wiley, V.; Pitt, J.J. Pseudo-glutarylcarnitinaemia in medium-chain-acyl-CoA dehydrogenase deficiency detected by tandem mass spectrometry newborn screening. J. Inherit. Metab. Dis., 2004, 27(4), 465-471.
128. Nelson, D.L.; Cox, M.M. Lehninger principles of biochemistry, 4th ed.; W.H. Freeman Company: New York, 2005.
129. Santra, S.; Hendriksz, C. How to use acylcarnitine profiles to help diagnose inborn errors of metabolism. Arch. Dis. Educ. Pract. Ed., 2010, 95(5), 151-156.
130. Lin, H.J.; Neidich, J.A.; Salazar, D.; Thomas-Johnson, E.; Ferreira, B.F.; Kwong, A.M.; Lin, A.M.; Jonas, A.J.; Levine, S.; Lorey, F.; Rosenblatt,
131. American College of Medical Genetics and Genomics. http://www.acmg.net/ AM/Template.cfm?Section=NBS-ACT-Sheets-and-A lgorithms-Table&Template=/CM/ HTMLDisplay.cfm&ContentID=5072 (Accessed Nov 11, 2011).
132. Camfield, C.S.; Joseph, M.; Hurley, T.; Campbell, K.; Sanderson, S.; Cam-field, P.R. Optimal management of phenylketonuria: a centralized expert team is more successful than a decentralized model of care. J. Pediatr., 2004, 145, 53-57.
133. Declaration of Common Principles on Centres of Expertise and European Reference Networks for Rare Diseases. http://www.eurordis.org/sites/default/ files/publications/ Declaration-Centres%20of%20Expertise-nov08.pdf (Accessed Jul 19, 2012).
134. Couce, M.L.; Castiñeiras, D.E.; Bóveda, M.D.; Baña, A.; Cocho, J.A.; Iglesias, A.J.; Colón, C.; Alonso-Fernández, J.R.; Fraga, J.M. Evaluation and long-term follow-up of infants with inborn errors of metabolism identified in an expanded screening programme. Mol. Genet. Metab., 2011, 104(4), 470-475.